MetaVia (NASDAQ:MTVA) Coverage Initiated at HC Wainwright

HC Wainwright initiated coverage on shares of MetaVia (NASDAQ:MTVAFree Report) in a research report sent to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for MetaVia’s Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($3.87) EPS, Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.

MetaVia Stock Up 2.5 %

Shares of NASDAQ MTVA opened at $2.03 on Monday. MetaVia has a 1 year low of $1.51 and a 1 year high of $6.75.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Further Reading

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.